Tags

Type your tag names separated by a space and hit enter

Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2009 Jul; 11(7):641-64.DO

Abstract

Obesity is considered as a major health problem, as its prevalence continuously rises worldwide. One of the common health consequences of obesity is type 2 diabetes mellitus. Therefore, antiobesity management is a prerequisite in treating diabetic patients. Lifestyle modifications combined with pharmacological agents appear to be an effective approach. Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss. A potential association with cardiovascular side effects has been noted. Orlistat, a gastric and pancreatic lipase inhibitor, also achieves significant weight loss and improves glycaemic status, but it has gastrointestinal side effects. Rimonabant, the first endocannabinoid CB1 antagonist, is associated with weight reduction and it improves diabetic parameters; nevertheless, it is associated with psychiatric disorders; indeed, a recently conducted safety review led to the temporal suspension of its commercialization. The above-mentioned medications seem to be currently useful agents for treating obesity in patients with type 2 diabetes mellitus. Other medications used for diabetes management, such as exenatide, liraglutide and pramlintide, have also shown body weight reduction. Ongoing research is needed to scrutinize the precise impact of these agents in the daily clinical practice of management of obesity in patients with type 2 diabetes mellitus.

Authors+Show Affiliations

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19236442

Citation

Choussein, Souzana, et al. "Effect of Antiobesity Medications in Patients With Type 2 Diabetes Mellitus." Diabetes, Obesity & Metabolism, vol. 11, no. 7, 2009, pp. 641-64.
Choussein S, Makri AA, Frangos CC, et al. Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(7):641-64.
Choussein, S., Makri, A. A., Frangos, C. C., Petridou, E. T., & Daskalopoulou, S. S. (2009). Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism, 11(7), 641-64. https://doi.org/10.1111/j.1463-1326.2008.01026.x
Choussein S, et al. Effect of Antiobesity Medications in Patients With Type 2 Diabetes Mellitus. Diabetes Obes Metab. 2009;11(7):641-64. PubMed PMID: 19236442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of antiobesity medications in patients with type 2 diabetes mellitus. AU - Choussein,Souzana, AU - Makri,Angeliki A, AU - Frangos,Constantinos C, AU - Petridou,Eleni Th, AU - Daskalopoulou,Stella S, Y1 - 2009/02/18/ PY - 2009/2/25/entrez PY - 2009/2/25/pubmed PY - 2010/6/5/medline SP - 641 EP - 64 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 11 IS - 7 N2 - Obesity is considered as a major health problem, as its prevalence continuously rises worldwide. One of the common health consequences of obesity is type 2 diabetes mellitus. Therefore, antiobesity management is a prerequisite in treating diabetic patients. Lifestyle modifications combined with pharmacological agents appear to be an effective approach. Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss. A potential association with cardiovascular side effects has been noted. Orlistat, a gastric and pancreatic lipase inhibitor, also achieves significant weight loss and improves glycaemic status, but it has gastrointestinal side effects. Rimonabant, the first endocannabinoid CB1 antagonist, is associated with weight reduction and it improves diabetic parameters; nevertheless, it is associated with psychiatric disorders; indeed, a recently conducted safety review led to the temporal suspension of its commercialization. The above-mentioned medications seem to be currently useful agents for treating obesity in patients with type 2 diabetes mellitus. Other medications used for diabetes management, such as exenatide, liraglutide and pramlintide, have also shown body weight reduction. Ongoing research is needed to scrutinize the precise impact of these agents in the daily clinical practice of management of obesity in patients with type 2 diabetes mellitus. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/19236442/Effect_of_antiobesity_medications_in_patients_with_type_2_diabetes_mellitus_ L2 - https://doi.org/10.1111/j.1463-1326.2008.01026.x DB - PRIME DP - Unbound Medicine ER -